https://www.biospace.com/xeris-pharmaceuticals-doses-first-patient-in-phase-2-trial-evaluating-its-developmental-ready-to-use-glucagon-in-patients-at-risk-from-hypoglycemia-following-bariatric-surgery
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental...
Jun 27, 2019 - Xeris Pharmaceuticals, Inc. announced that is has dosed the first subject in a Phase 2 trial with its developmental ready-to-use glucagon in patients who...
phase 2 trialxeris pharmaceuticalsfirst patient